Ginkgo Bioworks Holdings Inc - DNA STOCK NEWS

Visolis has partnered with Ginkgo Bioworks (NYSE: DNA) to enhance the production of bio-based isoprene and sustainable aviation fuels (SAF). This collaboration aims to leverage Ginkgo's strain engineering capabilities to improve microbial efficiency for producing a key feedstock ingredient. Bio-based isoprene is crucial for decarbonizing rubber tire manufacturing, while SAF offers a lower carbon intensity alternative in aviation. Visolis employs a novel two-step process for isoprene production, enhancing stability and reliability. The partnership is expected to optimize production processes, with both companies expressing pride in contributing to carbon-negative solutions.

Ginkgo Bioworks is hosting its annual conference, Ferment, on April 19, 2023, in Boston. The event aims to unite diverse stakeholders in the synthetic biology sector, showcasing new service offerings such as Ginkgo Enzyme Services, which enhances enzyme research and development across industries like pharmaceuticals and agriculture. CEO Jason Kelly will discuss outsourcing R&D benefits, emphasizing Ginkgo's integrated capabilities in strain optimization and gene therapy services. Live streaming is available for those unable to attend in person. The conference features expert presentations and panels covering topics like biosecurity and innovation in health.

Cambrium and Ginkgo Bioworks have successfully completed a partnership focused on optimizing the design of microbes for protein production using generative AI. This collaboration utilized Cambrium's Cloud Protein AI platform alongside Ginkgo's ultra high-throughput screening technology, significantly enhancing protein production processes. Key achievements include the generation of valuable data for strain optimization, identification of new engineering targets, and development of efficient biomanufacturing methods. The project received co-funding from Swiss and German governmental bodies as part of the Eurostars initiative, highlighting its innovative approach to data-driven metabolic engineering.

Ginkgo Bioworks (NYSE: DNA) and Syngenta Seeds announced a research partnership to explore novel traits for future seed development. This collaboration utilizes Ginkgo's advanced protein engineering and high-throughput screening technologies, aimed at enhancing the resilience and health of crops for farmers. The partnership reflects an increasing trend in agriculture towards collaborative innovation, addressing global agricultural challenges through diverse expertise. Ginkgo's Vice President, Magalie Guilhabert, expressed enthusiasm for leveraging their unique technologies to support Syngenta in delivering innovative products to the agricultural sector.

On April 14, 2023, Ginkgo Bioworks (NYSE: DNA) announced a Memorandum of Understanding with the Institut National de la Recherche Biomédicale (INRB) in the Democratic Republic of the Congo (DRC). The partnership aims to enhance biosecurity capabilities in the region's public health institutions. Ginkgo's unit, Concentric by Ginkgo, plans to equip INRB with essential tools, training, and data infrastructure to leverage genomic technologies. This initiative is a key step in building a biosecurity platform that can serve the DRC and its neighbors, addressing the urgent need for effective pathogen monitoring in low-resource areas. Both organizations recognize the importance of collaboration to improve global health security and respond to biological threats effectively.

Ginkgo Bioworks (NYSE: DNA) has announced a partnership with the Wisconsin Alumni Research Foundation (WARF) to develop enhanced GD2 CAR T-cell therapies for solid tumors. The collaboration will leverage Ginkgo's proprietary high-throughput combinatorial CAR discovery platform to create next-generation therapies aimed at addressing T-cell exhaustion. Professors Krishanu Saha and Christian Capitini from the University of Wisconsin-Madison will lead the research efforts. The partnership aims to validate novel CAR designs in high-throughput in vitro and in vivo settings, ultimately improving treatment options for pediatric neuroblastoma. CAR T-cell therapies have shown promise in oncology, predominantly in blood cancers, and this initiative seeks to extend their efficacy to solid tumors, which account for 90% of adult cancers.

Ginkgo Bioworks (NYSE: DNA) will host its annual conference, Ferment, on April 19, 2023, in Boston, MA. This event aims to connect various stakeholders from the synthetic biology ecosystem, including shareholders, customers, and academics. Due to reaching in-person capacity, a video livestream will be made available to the public on the company’s investor relations website. Ginkgo Bioworks is a leader in cell programming, providing services across multiple markets, including food, pharmaceuticals, and biosecurity through its Concentric unit. For more details, visit ginkgobioworks.com.

Sensible Biotechnologies has successfully secured a $4.2 million pre-seed funding round aimed at enhancing its cell-based platform for the efficient manufacturing of high-quality mRNA. The funding, led by BlueYard Capital and supported by notable investors such as Y Combinator and Recode Health Ventures, will facilitate the optimization and scalability of the company's mRNA production capabilities. This initiative is vital as current manufacturing methods struggle with quality and scalability issues. The investment follows a strategic partnership with Ginkgo Bioworks (NYSE: DNA), which will help accelerate the development of Sensible's innovative platform. The funding marks a significant step towards unlocking the potential of mRNA technology for therapeutic applications.